Kratom (Mitragyna speciosa)

The 2016 DEA Scheduling Attempt: The Public Comment Response

In August 2016, the DEA announced its intention to place mitragynine and 7-hydroxymitragynine on Schedule I of the Controlled Substances Act — the most restrictive classification, reserved for compounds with high abuse potential and no accepted medical use. The announcement, published in the Federal Register, triggered an extraordinary public response: the AKA organized a coordinated comment campaign that generated over 23,000 public comments in a matter of weeks — an unprecedented response to a scheduling notice. Congress members received thousands of constituent letters. A White House petition exceeded the threshold for official response. The DEA withdrew the scheduling notice in October 2016, stating it would conduct a more thorough scientific evaluation — a retreat that has not been replicated in the history of the DEA scheduling process.

The 2016 public comment response is the defining moment in Kratom regulatory history. It demonstrated that a large, organized consumer base was willing to engage at scale with the regulatory process — and that the DEA, when confronted with a massive negative response to a scheduling announcement, was willing to reverse course. The episode established a precedent: Kratom consumers are organized and politically active. This political organization has since been the primary defense against further DEA scheduling attempts — every subsequent scheduling signal has been met with organized advocacy response.

r/kratom: The 200K-Member Community as Harm Reduction Infrastructure

r/kratom, with over 200,000 members, functions as a multi-purpose community: harm reduction information, vendor quality discussion, dose guidance, withdrawal management support, and regulatory response coordination. The community discusses Kratom as a tool for opioid harm reduction with unusual specificity — conversations distinguish between using Kratom as a transition off pharmaceutical opioids, as a tool to manage opioid cravings, and as a standalone pain management compound for patients who cannot access or tolerate standard pharmaceutical options.

The harm reduction framing in r/kratom is substantively sophisticated by consumer community standards: members discuss the limitations of available evidence, distinguish between anecdotal reports and clinical observations, and share harm reduction practices (dosage titration, cross-tolerance management, withdrawal mitigation) with an awareness that they are operating without clinical guidance. The community acknowledges the dependency potential and discusses tapering protocols — a sign that the community is not uniformly promoting uncritical use but is engaging with the compound complexity.

Vendor quality is a persistent topic in r/kratom. The community has developed informal quality markers for commercial Kratom products — distinguishing between vendors who provide third-party testing and those who do not, discussing the correlation between specific vendors and reported adverse events, and maintaining a shared reputation system for product quality and consistency. The community-developed vendor quality system is a functional response to the absence of regulatory quality standards — it substitutes for the FDA oversight that pharmaceutical products receive.

The American Kratom Association (AKA) and the GMP Certification Program

The American Kratom Association, founded in 2014, is the primary industry organization representing the Kratom advocacy position. The AKA has taken a two-track approach to regulatory engagement: political lobbying at the state and federal level (fighting scheduling legislation, supporting state-level consumer protection laws) and industry self-regulation through its GMP (Good Manufacturing Practice) certification program. The GMP program certifies member companies that meet cGMP-quality standards for Kratom manufacturing — including testing for contaminants (salmonella, E. coli, heavy metals), alkaloid potency verification, and standard operating procedures for production and packaging.

The AKA GMP certification program is a response to the product quality crisis (see Uncertainty article) that has repeatedly threatened the Kratom community — including the 2018 salmonella outbreak that the CDC attributed to contaminated Kratom products. The certification program is voluntary, self-funded by participating companies, and not legally required. Its effectiveness depends on consumer awareness and preference for certified products — market forces that have had partial uptake but have not resolved the broader quality problem in the industry. Non-certified vendors continue to operate and sell products without meeting cGMP standards.

Kratom Bars: The Retail Experience

A small but growing retail format — Kratom bars or Kratom dispensaries — has emerged in several states where Kratom is legal, modeled loosely on coffee shop culture for a psychoactive compound. These establishments offer Kratom in various preparation forms (toss-and-wash powder, brewed tea, encapsulated products) for on-premise consumption or retail purchase. The Kratom bar model is most established in Florida and Colorado, with operators framing the format as providing education, quality verification, and a controlled environment for use. The bar format also serves a social harm reduction function: users consuming Kratom in a space with knowledgeable operators (who can provide dose guidance and identify adverse response signs) rather than alone at home.

The Kratom bar model has faced legal challenges in states where local authorities interpret Kratom sale or consumption differently from the state-level legality. Several localities have passed local bans on Kratom sale or possession despite state-level legalization — creating a patchwork regulatory environment that complicates the bar business model. The legal ambiguity has been partially addressed by state preemption laws in several states that prevent local governments from banning Kratom sale.

The Harm Reduction vs. Another Opioid Framing Debate

The core cultural debate around Kratom splits into two positions that are more about framing than pharmacology: the harm reduction position frames Kratom as a tool for reducing opioid overdose deaths — a transition compound that allows opioid users to self-manage without the overdose risk of fentanyl-adulterated street drugs. The "another opioid" position frames Kratom as a partial mu-opioid agonist that is being marketed as safe while carrying genuine addiction and harm potential that is under-reported. Both framings are partially accurate, and the factual question of which framing is more representative of the population-level Kratom experience is the one question that controlled trials would resolve.

The harm reduction framing is supported by: Grundmann 2017 data (35% using for opioid withdrawal); poison control call data ^[1]; addiction medicine specialists who have observed patients transition from lethal opioid use to Kratom dependency and stabilize. The "another opioid" position is supported by: Boyer 2008 (Kratom dependency and withdrawal are real); Singh 2016 (tolerance and dose escalation in long-term users); FDA 8-Factor Analysis (classifying Kratom as an opioid with abuse potential); deaths where Kratom was involved alongside other substances (noting that Kratom in combination with other CNS depressants substantially increases fatality risk).

See also: CBD — the regulatory tension is parallel: FDA issued import alerts, the 8-Factor Analysis approach is similar to how CBD was initially classified, and both compounds remain in legal gray zones where state legality diverges from federal classification; Low-Dose Naltrexone — shares the harm reduction framing and the opioid-alternative community advocacy pattern; Peptide Therapy — the gray-market supply chain, community-developed quality verification, and the FDA-compounding pharmacy tension all parallel Kratom; the partial mu-opioid agonist mechanism is the specific pharmacological characteristic that makes Kratom operate in the same harm reduction/harm escalation debate space as LDN.

Zero FDA-Approved Clinical Trials: The Structural Evidence Problem

Kratom has zero completed FDA clinical trials for any indication. This is not an accidental gap — it is a structural condition of the regulatory environment. The DEA scheduling risk makes conducting clinical research on Schedule I compounds (if mitragynine were scheduled) or compounds under FDA import alert logistically and legally challenging. No pharmaceutical company has an incentive to fund Kratom clinical trials: mitragynine is not patent-protected, and any positive clinical data would immediately benefit competitors. The result is that every piece of evidence about Kratom efficacy, safety, and optimal use is epidemiological, not clinical — meaning it is subject to the biases, limitations, and confounders inherent in non-experimental research.

The absence of clinical trials means that the foundational questions — does Kratom reduce opioid use compared to standard treatment? does it reduce pain compared to placebo? what is the long-term safety profile? — are unanswered. The survey evidence ^[1] shows what users believe about their own use; it does not show what would happen in a randomized controlled comparison to existing treatments. The case series ^[2] document dependency patterns; they do not show the incidence of dependency in the broader user population. The pharmacology ^[3] characterizes mechanisms; they do not establish that modulating those mechanisms produces clinical benefit.

The practical implication of the trial gap is that any person considering Kratom use — for pain, for opioid withdrawal, for any other purpose — is making a decision based on the equivalent of Phase I and Phase II observational evidence. They are effectively enrolled in an uncontrolled, unmonitored Phase I/II study, with no data monitoring, no adverse event reporting infrastructure, and no comparative outcome data.

The Deaths Attribution Problem: FDA vs. Eggleston

The FDA has cited 44 deaths associated with Kratom in its regulatory communications and Congressional testimony. This number is frequently cited by FDA and DEA officials as evidence of Kratom harm. The attribution is contested on methodological grounds. Eggleston et al. ^[4], published in Pharmacotherapy, analyzed data from the Toxicology Investigators Consortium (ToxIC) and the National Poison Data System (NPDS) — both systematic poisoning surveillance systems — and found that Kratom-associated fatalities almost universally involve co-administration with other substances: opioids (particularly fentanyl and tramadol), benzodiazepines, alcohol, or other CNS depressants. Deaths attributed to Kratom alone were found to be rare and poorly documented in most cases.

The FDA death count methodology — combining single-substance Kratom fatalities with multi-substance fatalities where Kratom was present — conflates two categorically different events. A death in which Kratom was present alongside fentanyl, alcohol, and benzodiazepines cannot be attributed to Kratom without accounting for the contribution of each substance. The standard toxicological methodology for assessing drug involvement in death requires attribution analysis that goes beyond "was this compound present at autopsy." The FDA cited number, while technically accurate (44 deaths occurred where Kratom was present), overstates Kratom contribution to mortality when the vast majority of those deaths involved at least one other substance.

However, the deaths that do occur in Kratom-polydrug combinations reveal a genuine risk: the partial mu-opioid agonist activity of Kratom combined with full opioid agonists, benzodiazepines, or alcohol produces synergistic respiratory depression. A user who takes Kratom to manage opioid cravings and then uses fentanyl-adulterated street drugs (under the assumption that their Kratom use protects them) is at substantially elevated overdose risk — because the partial agonist respiratory depression ceiling does not provide protection against full agonist overdose. The harm reduction argument that Kratom reduces opioid overdose mortality requires that Kratom users are substituting for opioids, not combining with them; the death data suggests some users are doing the latter.